莫林通过调节AMPK/mTOR/ULK1信号通路来促进人类PC3前列腺癌细胞的自
Fereshtesadat Fakhredini1, Hadis Alidadi2, Masoud Mahdavinia3
1Cellular and Molecular Research Center, Medical Basic Sciences Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran; Department of Anatomical Sciences, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
摩林是一种天然化合物,通过触发已编程细胞死亡 (细胞亡) 和自来对抗前列腺癌. 它激活AMP激活蛋白激酶 (AMPK) 和ULK1,同时抑制mTOR,导致癌细胞死亡.
科学领域:
- 分子生物学分子生物学
- 细胞生物学 细胞生物学
- 癌症研究 癌症研究
背景情况:
- AMP激活蛋白激酶 (AMPK) 通过调节自和亡,在抑制瘤生长方面发挥着至关重要的作用.
- 了解癌症进展背后的分子机制对于开发有效的治疗策略至关重要.
研究的目的:
- 为了研究莫林对PC3前列腺癌细胞的影响.
- 阐明AMPK/mTOR/ULK1通路和自在莫林诱导的抗癌作用中的作用.
主要方法:
- 用莫林和AICAR (AMPK激活剂) 治疗PC3细胞.
- 评估了细胞活力,细胞亡 (DAPI染色,Bax/Bcl-2比率,Caspase活性,Annexin V/PI) 和自标志物 (LC3B/LC3A比率,阿克里丁色,贝克林-1,ATG5,p62).
- 分析了p-AMPK,p-ULK1和p-mTOR的蛋白质水平.
主要成果:
- 莫林显著降低了PC3细胞活力和诱导的亡.
- 莫林治疗增加了p-AMPK和p-ULK1水平,同时降低了p-mTOR表达.
- 莫林促进了自,通过增加LC3B/LC3A比率和Beclin-1/ATG5表达来证明,并降低了p62水平.
- 艾卡尔增强了莫林的抗癌作用,进一步支持AMPK激活的作用.
结论:
- 莫林诱导PC3前列腺癌细胞中的亡和自细胞死亡.
- 该机制涉及AMPK/ULK1通路的激活和mTOR通路的抑制.
- 莫林显示出作为前列腺癌治疗剂的潜力.
更多相关视频
07:15Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
11:01Automated Imaging and Analysis for the Quantification of Fluorescently Labeled Macropinosomes
Published on: August 24, 2021
相关概念视频
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway
Autophagy
An autophagic pathway consists of a series of signaling events activated in response to diverse stress and physiological conditions such as food deprivation,...
Abnormal Proliferation
MAPK Signaling Cascades
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
